I would love to see a way to prospectively collect data on late effects. We have so many new drugs coming out and it would be great to initiate this now so we can start collecting late effect data. So much of our knowledge comes from retrospective research collections. This database could be great way to more accurately learn when these late effects develop and what are patients are at risk for with new drugs.
1. would include any molecular data on tumor (ie Foundation One, MATCH, institutional)
2. include better family histories (especially first degree relatives - specifically other tumors (benign and malignant), immune problems, hematologic problems
3. include any known... more »
CancerLINQ, a subsidiary of the American Society of Clinical Oncology, is a database of individual patient data from over 100 practices of patients who are NOT enrolled in clinical trials. It represents real-world patient journeys. "CancerLinQ Discovery®️ enables the oncology community to translate big data from CancerLinQ®️'s pool of de-identified data... more »
The data for this proposed database would be obtained from hospitals and research facilities, not just from this country, but from other... more »
• Proteomic data with clinical correlation
• Safety and toxicity data profiles at different time points
• Treatment regimen
• Outcomes data
• Socioeconomic and demographic data
• Biospecimens... more »
- Create a centralized patient data registry that includes a myriad of useful... more »
The objective of this idea is to expand the capacity of SEER to support research on the diagnosis, treatment, and outcomes of children's cancers. This project proposes to enhance SEER real world data with imaging and liquid biopsy data to support supplement clinical trials through pilot demonstration studies.